At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 58 enrolled
Drug / intervention
ziv-aflibercept +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas
In Brief
A Phase 2 clinical trial evaluating ziv-aflibercept, pharmacological study, and 1 other intervention for Adult Anaplastic Astrocytoma and 4 related conditions. Completed, enrolled 58 participants across 7 sites.
Detailed Summary
This phase II trial is studying how well VEGF Trap works in treating patients with recurrent malignant or anaplastic gliomas that did not respond to temozolomide. VEGF Trap may stop the growth of malignant or anaplastic gliomas by blocking blood flow to the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
First PostedAug 2006
Primary CompletionDec 2011
Study CompletionOct 2012
TodayJul 2026
First PostedAug 29, 2006
Enrollment StartAug 1, 2006
Primary CompletionDec 1, 2011
Study CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 19.8 years ago
Interventions
ziv-afliberceptbiological
Given IV
pharmacological studyother
correlative studies
laboratory biomarker analysisother
correlative studies